ATHIRA PHARMA INC (ATHA)
US04746L1044 - Common Stock
Tuesday Sector Leaders: Manufacturing, Drugs
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Wednesday 6/26 Insider Buying Report: PX, ATHA
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients...
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
First-in-human, dose escalation study to evaluate safety, tolerability and pharmacokinetics in healthy volunteers with trial completion expected by year-end 2024
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)...
Athira Pharma to Participate in Upcoming June Conferences
Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer’s Disease on Track for Second Half of 2024
Athira Pharma to Participate in Upcoming June Conferences
Management to Highlight Robust Pipeline in Neurodegenerative Diseases with Key Phase 2/3 LIFT-AD Topline Data in Alzheimer’s Disease on Track for Second...
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on...
ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Athira Pharma (NASDAQ:ATHA) just reported results for the first quarter of 2024...
ATHA Stock Earnings: Athira Pharma Beats EPS for Q1 2024
ATHA stock results show that Athira Pharma beat analyst estimates for earnings per share the first quarter of 2024.
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates...
Athira Pharma to Participate in Upcoming May Conferences
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
Experienced clinical development leader with a strong track record of advancing therapeutics from early development to approval and commercialization
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer....
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Fosgonimeton counteracts mechanisms of amyloid-beta (Aβ)-driven toxicity and demonstrates neuroprotection in preclinical models of Alzheimer’s disease
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease ...
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
Presentation to highlight therapeutic potential of Athira’s small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
Presentation to highlight therapeutic potential of Athira’s small molecules targeting the neurotrophic HGF system in neurodegenerative disorders, including...
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s & Parkinson’s Diseases at AD/PD™ 2024...
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates...
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Results demonstrate ATH-1105 is neuroprotective, preserves motor and nerve function and extends survival in preclinical models of ALS
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)...
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update...
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease ...
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
Exploratory findings add to increasing body of clinical and preclinical data supporting positive modulation of the neurotrophic HGF system as a potential...
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in neurodegenerative diseases, including Alzheimer’s disease
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
Company Presentation to highlight novel therapeutic candidates targeting the HGF neurotrophic system in late-stage clinical development in...
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
Presentation to highlight preclinical data from ATH-1105, Athira’s potential treatment candidate for amyotrophic lateral sclerosis (ALS)